Saccomano Nicholas A 4

What Happened

• Nicholas A. Saccomano, President, CEO and Director of OnKure Therapeutics (OKUR), was granted derivative securities covering 330,000 shares on April 1, 2026. The Form 4 reports the acquisition as an award (derivative) with a reported dollar amount of $0 on the filing excerpt provided.
• This award is an option-style grant: 1/48th of the shares subject to the option vest on May 1, 2026 and each month thereafter, subject to continued service — i.e., monthly vesting over 48 months (4 years). The filing does not disclose an exercise price or other economic terms in the excerpt provided.

Key Details

• Transaction date: 2026-04-01; Filing date: 2026-04-03 (no late filing indicated).
• Award: 330,000 shares reported as a derivative acquisition; amount reported on Form 4 = $0 (exercise price/economic terms not shown in provided data).
• Vesting footnote: “1/48th of the shares subject to the option shall vest on May 1, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.”
• Shares owned after the transaction: not specified in the provided excerpt.
• Transaction code: A (Award/Grant).

Context

• This is a compensation grant (an option award) rather than an open-market purchase or sale. Such grants are common for executive compensation and do not by themselves indicate immediate buying or selling in the market.
• The award vests over time; Saccomano will only realize shares as portions vest (and, for options, if/when he exercises them and any applicable exercise price is paid).